JP5695627B2 - 骨造成のための注射用フィブリン組成物 - Google Patents
骨造成のための注射用フィブリン組成物 Download PDFInfo
- Publication number
- JP5695627B2 JP5695627B2 JP2012237629A JP2012237629A JP5695627B2 JP 5695627 B2 JP5695627 B2 JP 5695627B2 JP 2012237629 A JP2012237629 A JP 2012237629A JP 2012237629 A JP2012237629 A JP 2012237629A JP 5695627 B2 JP5695627 B2 JP 5695627B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- composition
- bone
- contrast agent
- calcium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 37
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 37
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 229950003499 fibrin Drugs 0.000 title claims abstract description 37
- 238000002347 injection Methods 0.000 title claims description 31
- 239000007924 injection Substances 0.000 title claims description 31
- 230000011164 ossification Effects 0.000 title claims description 13
- 239000002872 contrast media Substances 0.000 claims abstract description 61
- 239000002245 particle Substances 0.000 claims abstract description 57
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 49
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 42
- 208000020084 Bone disease Diseases 0.000 claims abstract description 11
- 108090000190 Thrombin Proteins 0.000 claims description 41
- 229960004072 thrombin Drugs 0.000 claims description 41
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 37
- 108010049003 Fibrinogen Proteins 0.000 claims description 33
- 102000008946 Fibrinogen Human genes 0.000 claims description 33
- 229940012952 fibrinogen Drugs 0.000 claims description 33
- 230000001172 regenerating effect Effects 0.000 claims description 22
- 239000001506 calcium phosphate Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 16
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 13
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 12
- 235000011010 calcium phosphates Nutrition 0.000 claims description 12
- 230000037176 bone building Effects 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 9
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 8
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 8
- 229960004359 iodixanol Drugs 0.000 claims description 7
- 229960001025 iohexol Drugs 0.000 claims description 7
- 150000002894 organic compounds Chemical class 0.000 claims description 7
- -1 iotolol Chemical compound 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- RHISTIGVAKTTCM-UHFFFAOYSA-N 5-[[3-[3,5-bis(1,3-dihydroxypropan-2-ylcarbamoyl)-n-(2-hydroxyethyl)-2,4,6-triiodoanilino]-3-oxopropanoyl]-(2-hydroxyethyl)amino]-1-n,3-n-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound IC=1C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C(I)C=1N(CCO)C(=O)CC(=O)N(CCO)C1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I RHISTIGVAKTTCM-UHFFFAOYSA-N 0.000 claims description 4
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 229960005423 diatrizoate Drugs 0.000 claims description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 4
- 229960000780 iomeprol Drugs 0.000 claims description 4
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 claims description 4
- 229960004647 iopamidol Drugs 0.000 claims description 4
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 4
- 229960002603 iopromide Drugs 0.000 claims description 4
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims description 4
- 229960003194 meglumine Drugs 0.000 claims description 4
- 229960000554 metrizamide Drugs 0.000 claims description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 4
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims description 3
- 210000000245 forearm Anatomy 0.000 claims description 3
- 229960004537 ioversol Drugs 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 210000001217 buttock Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 18
- 239000007972 injectable composition Substances 0.000 abstract description 9
- 230000003416 augmentation Effects 0.000 abstract 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 12
- 239000004926 polymethyl methacrylate Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 230000002188 osteogenic effect Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 6
- 238000002594 fluoroscopy Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000001879 gelation Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010010214 Compression fracture Diseases 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229960003182 iotrolan Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 208000028528 solitary bone cyst Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/4601—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor for introducing bone substitute, for implanting bone graft implants or for compacting them in the bone cavity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2825—Femur
- A61F2002/2828—Femoral head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
- A61F2310/00377—Fibrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/202—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with halogen atoms, e.g. triclosan, povidone-iodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/44—Radioisotopes, radionuclides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、フィブリン、造影剤、およびカルシウム塩含有粒子を含む骨造成のための生分解性注射用組成物、ならびに骨疾患を患う患者の骨造成法であって、当該骨の非石灰化部分または中空部分に当該組成物を注射する工程を包含する方法に関する。
例えば、経皮的骨造成は、下記の適応症に用いられてきた椎体形成技術および亀背形成技術を含む:有痛性血管腫、骨粗しょう症性圧迫骨折、外傷性圧迫骨折、および有痛性脊椎転移。一例としては、ポリメタクリル酸メチル(PMMA)骨セメントの経皮的送達による骨折した椎体の修復が挙げられる。この治療は、椎骨の鎮痛および高さの回復に有効である。蛍光透視法を用いて標的とする椎骨を特定し、椎体内に套管針を入れる。PMMAは、椎体の片側(一方向)または両側(双方向)に送達可能であり、蛍光透視法を用いてこの送達を監視し、セメントが漏出または移動することなく確実にボーラス形状を留めるようにする。
透視鏡の送達を容易にしている。骨および接着特性に対する硫酸バリウムの長期効果は完全には知られていない。
このため、上述した欠点を克服する注射用骨造成組成物に対する強い要望が存在する。
本発明はまた、以下の項目を提供する。
(項目1)
注射用骨造成組成物の多成分系であって、
フィブリノゲンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つの造影剤を含む成分(c)と;
直径が約200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含む、多成分系。
(項目2)
上記成分(a)〜(d)は溶液中に存在しており、少なくとも成分(a)は、成分(b)と空間的に分離されている、項目1に記載の多成分系。
(項目3)
上記造影剤は、少なくとも1つのヨウ素含有有機化合物を含む、項目1に記載の多成分系。
(項目4)
上記造影剤は、ジアトリゾアート(メグルミン)、イオデコール、イオジキサノール、イオフラトール、イオグラミド、イオヘキソール、イオメプロール、イオパミドール、イオプロミド、イオトロール、イオベルソール、イオキサグレート、およびメトリザミド、ならびにそれらの混合物で構成される群から選択される、項目3に記載の多成分系。
(項目5)
上記カルシウム塩含有粒子は、リン酸三カルシウム、アルファ−リン酸三カルシウム、ベータ−リン酸三カルシウム、リン酸カルシウム、リン酸カルシウムの多形、ヒドロキシアパタイト、炭酸カルシウム、硫酸カルシウム、およびそれらの任意の組み合わせで構成される群から選択される、項目1に記載の多成分系。
(項目6)
上記カルシウム塩含有粒子は、リン酸三カルシウム、アルファ−リン酸三カルシウム、ベータ−リン酸三カルシウム、およびリン酸カルシウム、ならびにそれらの混合物で構成される群から選択され、かつ/または該カルシウム塩含有粒子は、Ca/P比が約1.5
〜約2の範囲である、項目5に記載の多成分系。
(項目7)
上記フィブリノゲン成分(a)中のフィブリノゲンの量は、約10〜約200mg/mlの範囲である、項目1に記載の多成分系。
(項目8)
上記トロンビン成分(b)中のトロンビンの量は、最終凝塊組成物において少なくとも約1IU/mlである、項目1に記載の多成分系。
(項目9)
上記成分(c)中の造影剤の量は、最終凝塊組成物において約100〜約800mg/mlの範囲である、項目1に記載の多成分系。
(項目10)
上記成分(d)中の少なくとも1種類のカルシウム塩含有粒子の量は、上記最終凝塊組成物に対して約1〜約50%w/wの範囲である、項目1に記載の多成分系。
(項目11)
上記成分(a)中のフィブリノゲンの量は、約10〜約200mg/mlの範囲であり、上記成分(b)中のトロンビンの量は、上記最終凝塊組成物において少なくとも約1IU/mlであり、上記成分(c)に含有される造影剤の量は、該最終凝塊組成物において約100〜約800mg/mlの範囲であり、上記成分(d)中の少なくとも1種類のカルシウム塩含有粒子の量は、該最終凝塊組成物に対して約1〜約50%w/wの範囲である、項目1に記載の多成分系。
(項目12)
上記カルシウム塩含有粒子は、直径が約100μm未満である、項目1に記載の多成分系。
(項目13)
上記カルシウム塩含有粒子は、直径が約50μm未満である、項目12に記載の多成分系。
(項目14)
注射用骨造成組成物の多成分系であって、
フィブリノゲンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つの造影剤を含む成分(c)と;
直径が約200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、を含み、
該成分(a)〜(d)の1つ以上または全ては、固体状で存在する、多成分系。
(項目15)
注射用骨造成組成物であって、
フィブリンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つの造影剤を含む成分(c)と;
直径が約200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含む、組成物。
(項目16)
上記造影剤は、少なくとも1つのヨウ素含有有機化合物を含む、項目15に記載の注射用骨造成組成物。
(項目17)
上記適切な造影剤は、ジアトリゾアート(メグルミン)、イオデコール、イオジキサノール、イオフラトール、イオグラミド、イオヘキソール、イオメプロール、イオパミドール、イオプロミド、イオトロール、イオベルソール、イオキサグレート、およびメトリザミド、ならびにそれらの混合物で構成される群から選択される、項目15に記載の注射用骨造成組成物。
(項目18)
上記カルシウム塩含有粒子は、リン酸三カルシウム、アルファ−リン酸三カルシウム、ベータ−リン酸三カルシウム、リン酸カルシウム、リン酸カルシウムの多形、ヒドロキシアパタイト、炭酸カルシウム、硫酸カルシウム、およびそれらの任意の組み合わせで構成される群から選択される、項目15に記載の注射用骨造成組成物。
(項目19)
上記カルシウム塩含有粒子は、リン酸三カルシウム、アルファ−リン酸三カルシウム、ベータ−リン酸三カルシウム、およびリン酸カルシウム、ならびにそれらの混合物で構成される群から選択され、かつ/または該カルシウム塩含有粒子は、Ca/P比が約1.5
〜約2の範囲である、項目18に記載の注射用骨造成組成物。
(項目20)
上記成分(a)中のフィブリンの量は、上記最終凝塊組成物において約5〜約100mg/mlの範囲である、項目15に記載の注射用骨造成組成物。
(項目21)
上記成分(b)中のトロンビンの量は、上記最終凝塊組成物において少なくとも約1IU/mlである、項目15に記載の注射用骨造成組成物。
(項目22)
上記成分(c)中の造影剤の量は、上記最終凝塊組成物において約100〜約800mg/mlの範囲である、項目15に記載の注射用骨造成組成物。
(項目23)
上記成分(d)中の少なくとも1種類のカルシウム塩含有粒子の量は、上記最終凝塊組成物に対して約1〜約50%w/wの範囲である、項目15に記載の注射用骨造成組成物。
(項目24)
上記成分(a)中のフィブリンの量は、上記最終凝塊組成物において約5〜約100mg/mlの範囲であり、上記成分(b)中のトロンビンの量は、該最終凝塊組成物において少なくとも約1IU/mlであり、上記成分(c)に含有される造影剤の量は、該最終凝塊組成物において約100〜約800mg/mlの範囲であり、上記成分(d)中の少なくとも1種類のカルシウム塩含有粒子の量は、該最終凝塊組成物に対して約1〜約50%w/wの範囲である、項目15に記載の注射用骨造成組成物。
(項目25)
上記カルシウム塩含有粒子は、直径が約100μm未満である、項目15に記載の注射用骨造成組成物。
(項目26)
上記カルシウム塩含有粒子は、直径が約50μm未満である、項目25に記載の注射用骨造成組成物。
(項目27)
上記組成物はゲル化または凝塊した状態であり、骨の非石灰化部分または中空部分への注射に適した粘度を有する、項目15に記載の注入骨造成組成物。
(項目28)
骨疾患を患う患者の骨造成法であって、
フィブリンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つの造影剤を含む成分(c)と;
直径が約200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含む組成物を、該骨の非石灰化部分または中空部分に注射する工程を包含する、骨造成法。
(項目29)
上記骨疾患は、椎骨、臀部、および前腕の骨粗しょう症、ならびに良性および悪性病変からなる群から選択される、項目28に記載の骨造成法。
本発明の1つの局面は、注射用骨造成組成物の多成分系であって、
フィブリノゲンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つの造影剤を含む成分(c)と;
直径が約200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含む、多成分系に関する。
三カルシウム、ベータ−リン酸三カルシウム、およびリン酸カルシウムで構成される群から選択される。本発明のカルシウム塩含有粒子は、成分(d)が意味する範囲内で用いられる当該分野で公知の全ての市販化合物および/または混合物をさらに含む。他の例によると、本発明の多成分系のカルシウム塩含有粒子は、直径が約100μm未満(例えば、約50μm未満)である。本発明の1つの具体例では、成分(d)中の粒子の量は、最終凝塊組成物に対して約10〜約45%w/wまたは約30〜40%w/w等、約1〜約50%w/wの範囲である。
フィブリノゲンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つの造影剤を含む成分(c)と;
直径が約200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、を含み、
成分(a)〜(d)の1つ以上または全ては、固体状で存在する。
フィブリンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つの造影剤を含む成分(c)と;
直径が約200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含む、注射用骨造成組成物に関する。
材料:
フィブリンシーラント溶液
凍結乾燥したフィブリノゲン粉末をアプロチニン溶液を用いて91mg/mlの全凝固性タンパク質濃度に還元したもの。
5−[アセチル−[3−[アセチル−[3,5−ビス(2,3−ジヒドロキシプロピルカルバモイル)−2,4,6−トリヨード−フェニル]−アミノ]−2−ヒドロキシ−プロピル]−アミノ]−N,N’−ビス(2,3−ジヒドロキシプロピル)−2,4,6−トリヨード−ベンゼン−1,3−ジカルボキサミド
イオヘキソール
5−(アセチル−(2,3−ジヒドロキシプロピル)アミノ)−N,N’−ビス(2,3−ジヒドロキシプロピル)−2,4,6−トリヨード−ベンゼン−1,3−ジカルボキサミド
粒子
リン酸三カルシウム粒子(TCP)、35μm、球状(Plasma Biotal,Derby UK)
トロンビン500IU/ml
凍結乾燥したトロンビン粉末を5mlのトロンビン緩衝液を用いて500IU/mlの濃度に還元したもの。
40mMのCaCl2水溶液
80%または60%造影剤(イオジキサノールまたはイオヘキソール)および75IU
/mlトロンビン溶液をトロンビン希釈用緩衝液(40mMのCaCl2再蒸留水溶液)中で調製する。次いで、この溶液を均質化する。この溶液を遠心分離機にかけ泡を除去し、0.22μmフィルタで濾過して滅菌する。このフィブリノゲンをトロンビン/造影剤
(CA)と1:1の割合で混合する(このため、ゲル塊中のCA濃度は40または30%に半減する)。このため、2mlのトロンビン/造影剤溶液を5ml注射器に移す。2mlのフィブリノゲン(91mg/ml)を別の5ml注射器に移す。上記粒子(2μm程度)を最終的な凝塊の重量対容量百分率濃度(w/v)で取り込む。これらを重量測定し、別の5ml注射器に入れる。
ヨウ素化造影剤および粒子を含有する凝塊を実施例1に記載のとおりに調製する。これらの凝塊をマルチウェルプレートのウェルに入れた後、それらをゲルにする。それらの凝塊をウェルから取り出した後、汎用機械試験システムを用いてそれらの機械的性質を圧迫状態で検査する。
骨粗しょう症および加齢による骨塩量の低下により椎骨および大腿骨頭が骨折する場合が多くある。これらの部位に本発明に係る注射用骨造成組成物を注射することは、そのような負傷の治療に役立つ。注射用骨造成組成物の製剤は、実施例1に概説するように調製される。
をそれぞれヒト死体の椎骨および大腿骨頭に配置する。
に写真を撮影した(図2参照)。
頸骨幹の内筋膜(medial fascia)を切除し、頸骨を露出させる。プレートを骨幹に合った形状にして、スクリューを用いて骨に固定する。このプレートを再度取り外し、規格化された1cm全層欠損部位を作る。この部分を除去し、プレートを再度配置して、スクリューを再度挿入する。その後、注射用骨造成組成物を欠損部位に充填し、縫合糸で傷を閉じる。
Claims (20)
- 注射用骨造成組成物のための多成分系であって、
フィブリノゲンを含む成分(a)と;
トロンビンを含む成分(b)と;
少なくとも1つのヨウ素含有造影剤を含む成分(c)と;
直径が200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含む、多成分系。 - 注射用骨造成組成物であって、
フィブリンを含む成分(a’)と;
トロンビンを含む成分(b)と;
少なくとも1つのヨウ素含有造影剤を含む成分(c)と;
直径が200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含む、組成物。 - 前記成分(a)〜(d)は溶液中に存在しており、少なくとも成分(a)は、成分(b)と空間的に分離されている、請求項1に記載の多成分系。
- 前記フィブリノゲン成分(a)中のフィブリノゲンの量は、10〜200mg/mlの範囲である、請求項1に記載の多成分系。
- 前記トロンビン成分(b)中のトロンビンの量は、最終凝塊組成物において少なくとも1IU/mlである、請求項1に記載の多成分系。
- 前記成分(c)中の造影剤の量は、最終凝塊組成物において100〜800mg/mlの範囲である、請求項1に記載の多成分系。
- 前記成分(a)〜(d)の1つまたは複数または全ては、固体状で存在する、請求項1に記載の多成分系。
- 前記造影剤は、少なくとも1つのヨウ素含有有機化合物を含む、請求項1に記載の多成分系または請求項2に記載の注射用骨造成組成物。
- 前記造影剤は、ジアトリゾアート(メグルミン)、イオデコール、イオジキサノール、イオフラトール、イオグラミド、イオヘキソール、イオメプロール、イオパミドール、イオプロミド、イオトロール、イオベルソール、イオキサグレート、およびメトリザミド、ならびにそれらの混合物で構成される群から選択される、請求項8に記載の多成分系または注射用骨造成組成物。
- 前記カルシウム塩含有粒子は、リン酸三カルシウム、アルファ−リン酸三カルシウム、ベータ−リン酸三カルシウム、リン酸カルシウム、リン酸カルシウムの多形、ヒドロキシアパタイト、炭酸カルシウム、硫酸カルシウム、およびそれらの任意の組み合わせで構成される群から選択される、請求項1に記載の多成分系または請求項2に記載の注射用骨造成組成物。
- 前記カルシウム塩含有粒子は、リン酸三カルシウム、アルファ−リン酸三カルシウム、ベータ−リン酸三カルシウム、およびリン酸カルシウム、ならびにそれらの混合物で構成される群から選択され、かつ/または該カルシウム塩含有粒子は、Ca/P比が1.5〜
2の範囲である、請求項10に記載の多成分系または注射用骨造成組成物。 - 前記成分(a)中のフィブリンの量は、前記最終凝塊組成物において5〜100mg/mlの範囲である、請求項2に記載の注射用骨造成組成物。
- 前記成分(b)中のトロンビンの量は、前記最終凝塊組成物において少なくとも1IU/mlである、請求項2に記載の注射用骨造成組成物。
- 前記成分(c)中の造影剤の量は、前記最終凝塊組成物において100〜800mg/mlの範囲である、請求項2に記載の注射用骨造成組成物。
- 前記成分(d)中の少なくとも1種類のカルシウム塩含有粒子の量は、前記最終凝塊組成物に対して1〜50%w/wの範囲である、請求項1に記載の多成分系または請求項2に記載の注射用骨造成組成物。
- 前記カルシウム塩含有粒子は、直径が100μm未満である、請求項1に記載の多成分系または請求項2に記載の注射用骨造成組成物。
- 前記カルシウム塩含有粒子は、直径が50μm未満である、請求項16に記載の多成分系または注射用骨造成組成物。
- 前記組成物はゲル化または凝塊した状態であり、骨の非石灰化部分または中空部分への注射に適した粘度を有する、請求項2に記載の注入骨造成組成物。
- 骨疾患を患う患者の骨造成用組成物であって、
フィブリンを含む成分(a’)と;
トロンビンを含む成分(b)と;
少なくとも1つのヨウ素含有造影剤を含む成分(c)と;
直径が200μm以下のカルシウム塩含有粒子を少なくとも1種類含む成分(d)と、
を含み、該組成物は、該骨の非石灰化部分または中空部分に注射されるものであることを特徴とする、骨造成用組成物。 - 前記骨疾患は、椎骨、臀部、および前腕の骨粗しょう症、ならびに良性および悪性病変からなる群から選択される、請求項19に記載の骨造成用組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80870906P | 2006-05-26 | 2006-05-26 | |
US60/808,709 | 2006-05-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009511354A Division JP5298010B2 (ja) | 2006-05-26 | 2007-04-17 | 骨造成のための注射用フィブリン組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013017842A JP2013017842A (ja) | 2013-01-31 |
JP5695627B2 true JP5695627B2 (ja) | 2015-04-08 |
Family
ID=38542028
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009511354A Expired - Fee Related JP5298010B2 (ja) | 2006-05-26 | 2007-04-17 | 骨造成のための注射用フィブリン組成物 |
JP2012237629A Expired - Fee Related JP5695627B2 (ja) | 2006-05-26 | 2012-10-29 | 骨造成のための注射用フィブリン組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009511354A Expired - Fee Related JP5298010B2 (ja) | 2006-05-26 | 2007-04-17 | 骨造成のための注射用フィブリン組成物 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9421302B2 (ja) |
EP (1) | EP2029184B1 (ja) |
JP (2) | JP5298010B2 (ja) |
KR (1) | KR101417148B1 (ja) |
CN (1) | CN101454028B (ja) |
AT (1) | ATE499120T1 (ja) |
AU (1) | AU2007268175B2 (ja) |
BR (1) | BRPI0712910B8 (ja) |
CA (1) | CA2651827C (ja) |
DE (1) | DE602007012693D1 (ja) |
DK (1) | DK2029184T3 (ja) |
ES (1) | ES2361574T3 (ja) |
MX (1) | MX2008014852A (ja) |
PL (1) | PL2029184T3 (ja) |
PT (1) | PT2029184E (ja) |
WO (1) | WO2007137653A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2029184B1 (en) | 2006-05-26 | 2011-02-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
KR101421750B1 (ko) * | 2006-05-26 | 2014-07-22 | 박스터 헬쓰케어 에스에이 | 주입가능한 골 결함 충전제 |
ES2381448T3 (es) | 2007-03-26 | 2012-05-28 | Baxter International Inc. | Material de relleno de huecos inyectable par el aumento de tejidos blandos |
JP5907656B2 (ja) * | 2007-04-23 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | ストロンチウム化合物を含むフィブリン組成物 |
US8062364B1 (en) | 2007-04-27 | 2011-11-22 | Knee Creations, Llc | Osteoarthritis treatment and device |
WO2009047361A2 (en) * | 2007-10-12 | 2009-04-16 | Kuros Biosurgery Ag | Injectable fibrin compositions for tissue augmentation comprising strontium salt |
WO2009114462A2 (en) * | 2008-03-11 | 2009-09-17 | Inmotion Musculoskeletal Institute | Local delivery of chemotherapeutic agents to skeletal metastases |
MX2010011440A (es) * | 2008-04-18 | 2010-12-21 | Kuros Biosurgery Ag | Un dispositivo de suministro, un kit que contiene el dispositivo, y metodo para operar el dispositivo. |
WO2010136588A2 (en) * | 2009-05-28 | 2010-12-02 | Profibrix B.V. | Dry powder fibrin sealant |
EP3370788A4 (en) * | 2015-11-02 | 2019-07-31 | Nanofiber Solutions, LLC | ELECTRO-spun fibers with contrast agents and method for producing same |
AU2017204355B2 (en) | 2016-07-08 | 2021-09-09 | Mako Surgical Corp. | Scaffold for alloprosthetic composite implant |
US20190343761A1 (en) | 2016-11-16 | 2019-11-14 | Persica Pharmaceuticals Ltd. | Antibiotic formulations for lower back pain |
CN111295094A (zh) | 2017-10-09 | 2020-06-16 | 泰尔茂比司特生物技术有限公司 | 冻干容器及使用冻干容器的方法 |
CN110947034B (zh) * | 2018-09-27 | 2022-05-27 | 上海市第十人民医院 | 一种生物活性磷酸钙/纤维蛋白复合的可注射骨修复水凝胶 |
JP2022525742A (ja) | 2019-03-14 | 2022-05-19 | テルモ ビーシーティー バイオテクノロジーズ,エルエルシー | 凍結乾燥用ローディングトレイ組立体及びシステム |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60256460A (ja) | 1984-05-31 | 1985-12-18 | 株式会社 ミドリ十字 | フイブリン及びリン酸カルシウム化合物を含有する骨欠損部及び空隙部充てん用組成物 |
EP0166263A1 (en) * | 1984-05-31 | 1986-01-02 | Green Cross Corporation | Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition |
US4696812A (en) * | 1985-10-28 | 1987-09-29 | Warner-Lambert Company | Thrombin preparations |
US4737411A (en) * | 1986-11-25 | 1988-04-12 | University Of Dayton | Controlled pore size ceramics particularly for orthopaedic and dental applications |
US4969888A (en) * | 1989-02-09 | 1990-11-13 | Arie Scholten | Surgical protocol for fixation of osteoporotic bone using inflatable device |
GB8916781D0 (en) * | 1989-07-21 | 1989-09-06 | Nycomed As | Compositions |
IT1240938B (it) | 1990-02-08 | 1993-12-27 | S.E.I.P.I. Societa' Esportazione Importazione Prodotti Industriali | Composizione vetrosa bioattiva per impianti ossei e prodotti ottenuti con tale composizione o che la comprendono |
WO1991017777A2 (en) | 1990-05-22 | 1991-11-28 | University Of Florida | Injectable bioactive glass compositions and methods for tissue reconstruction |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
FR2705235B1 (fr) * | 1993-05-13 | 1995-07-13 | Inoteb | Utilisation de particules d'un sel de calcium biocompatible et biorésorbable comme ingrédient actif dans la préparation d'un médicament destiné au traitement local des maladies déminéralisantes de l'os. |
US5549904A (en) | 1993-06-03 | 1996-08-27 | Orthogene, Inc. | Biological adhesive composition and method of promoting adhesion between tissue surfaces |
US6248110B1 (en) * | 1994-01-26 | 2001-06-19 | Kyphon, Inc. | Systems and methods for treating fractured or diseased bone using expandable bodies |
US6241734B1 (en) * | 1998-08-14 | 2001-06-05 | Kyphon, Inc. | Systems and methods for placing materials into bone |
JPH07213598A (ja) | 1994-02-07 | 1995-08-15 | Terumo Corp | 骨セメント |
FR2715853B1 (fr) | 1994-02-08 | 1996-04-26 | Centre Nat Rech Scient | Composition pour bio-matériau; procédé de préparation. |
FI101129B (sv) | 1995-01-13 | 1998-04-30 | Vivoxid Oy | Nya bioaktiva glas och deras användning |
US5676976A (en) * | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
US6287341B1 (en) * | 1995-05-19 | 2001-09-11 | Etex Corporation | Orthopedic and dental ceramic implants |
US5702715A (en) | 1995-10-27 | 1997-12-30 | Drying Technology | Reinforced biological sealants |
US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
US5782917A (en) * | 1996-02-26 | 1998-07-21 | Sunmed, Inc. | Intramedullary bone plug |
FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
GB9624918D0 (en) * | 1996-11-29 | 1997-01-15 | Nycomed Imaging As | Particulate components |
US20010016646A1 (en) * | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
US6096309A (en) * | 1997-06-18 | 2000-08-01 | Cohesion Technologies, Inc. | Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof |
US6475183B1 (en) * | 1998-06-03 | 2002-11-05 | Baxter International Inc. | Direct dual filling device for sealing agents |
DE69911609T2 (de) * | 1998-07-13 | 2004-07-01 | University Of Southern California, Los Angeles | Verfahren zur beschleunigen den zuwachs und heilen von knochen und knorpel |
WO2000007639A1 (en) | 1998-08-07 | 2000-02-17 | Tissue Engineering, Inc. | Bone precursor compositions |
US6605294B2 (en) * | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US6607535B1 (en) * | 1999-02-04 | 2003-08-19 | Kwan-Ho Chan | Universal bone cement plug and method of use |
DE19956503A1 (de) * | 1999-11-24 | 2001-06-21 | Universitaetsklinikum Freiburg | Spritzbares Knochenersatzmaterial |
SE517168C2 (sv) * | 2000-07-17 | 2002-04-23 | Bone Support Ab | En komposition för ett injicerbart ersättningsmaterial för benmineral |
JP2002060534A (ja) * | 2000-08-23 | 2002-02-26 | Shachihata Inc | 連続気泡を有するポリオレフィン多孔体 |
US6840952B2 (en) | 2000-12-07 | 2005-01-11 | Mark B. Saker | Tissue tract sealing device |
NO20014746D0 (no) | 2001-09-28 | 2001-09-28 | Clas M Kjoelberg | Smertelindrende middel |
US20050136038A1 (en) * | 2001-10-02 | 2005-06-23 | Isotis N.V. | Injectable calcium salt bone filler comprising cells |
SE522098C2 (sv) * | 2001-12-20 | 2004-01-13 | Bone Support Ab | Ett nytt benmineralsubstitut |
PT1465678E (pt) * | 2001-12-20 | 2007-10-09 | Bone Support Ab | Novo substituto mineral de osso |
JP4143823B2 (ja) * | 2002-03-14 | 2008-09-03 | ライオン株式会社 | 被覆粒子、洗剤組成物及び被覆粒子の製造方法 |
US7341716B2 (en) * | 2002-04-12 | 2008-03-11 | Boston Scientific Scimed, Inc. | Occlusive composition |
US7273523B2 (en) * | 2002-06-07 | 2007-09-25 | Kyphon Inc. | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof |
JP4446649B2 (ja) * | 2002-06-27 | 2010-04-07 | ライオン株式会社 | 発熱性貼付剤 |
EP1405647B1 (en) | 2002-10-03 | 2006-04-05 | Vivoxid Oy | Bioactive glass composition |
US7135027B2 (en) * | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
SE0300620D0 (sv) | 2003-03-05 | 2003-03-05 | Bone Support Ab | A new bone substitute composition |
PL1534305T3 (pl) | 2003-05-07 | 2007-03-30 | Osteologix As | Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie |
US6905723B2 (en) * | 2003-05-30 | 2005-06-14 | Depuy Products, Inc. | Strontium-substituted apatite coating |
KR101165614B1 (ko) | 2004-02-26 | 2012-07-18 | 오스테올로지스 에이에스 | 괴사성 골 질환의 예방 또는 치료에 사용하기 위한스트론튬 함유 화합물 |
US20050220882A1 (en) | 2004-03-04 | 2005-10-06 | Wilson Pritchard | Materials for medical implants and occlusive devices |
US7621952B2 (en) | 2004-06-07 | 2009-11-24 | Dfine, Inc. | Implants and methods for treating bone |
MY146697A (en) | 2004-07-09 | 2012-09-14 | Acetex Cyprus Ltd | Preparation of syngas for acetic acid synthesis by partial oxidation of methanol feedstock |
US8206448B2 (en) | 2004-10-29 | 2012-06-26 | Spinal Restoration, Inc. | Injection of fibrin sealant using reconstituted components in spinal applications |
US8403923B2 (en) | 2004-10-29 | 2013-03-26 | Spinal Restoration, Inc. | Injection of fibrin sealant in the absence of corticosteroids in spinal applications |
US20080287142A1 (en) * | 2004-07-22 | 2008-11-20 | Keighran Benjamin W | Location Dependent Content Provision |
EP1655042A1 (en) | 2004-11-02 | 2006-05-10 | Vivoxid Oy | A medical device |
WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
ES2593051T3 (es) * | 2005-01-06 | 2016-12-05 | Kuros Biosurgery Ag | Matrices suplementadas para la reparación de fracturas óseas |
US20060216321A1 (en) * | 2005-03-24 | 2006-09-28 | Sdgi Holdings, Inc. | Solvent based processing technologies for making tissue/polymer composites |
EP2029184B1 (en) | 2006-05-26 | 2011-02-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
KR101421750B1 (ko) * | 2006-05-26 | 2014-07-22 | 박스터 헬쓰케어 에스에이 | 주입가능한 골 결함 충전제 |
EP1903012B1 (en) * | 2006-09-20 | 2009-12-23 | Inion Oy | Bioactive glass compositions |
ES2381448T3 (es) * | 2007-03-26 | 2012-05-28 | Baxter International Inc. | Material de relleno de huecos inyectable par el aumento de tejidos blandos |
-
2007
- 2007-04-17 EP EP07724319A patent/EP2029184B1/en active Active
- 2007-04-17 JP JP2009511354A patent/JP5298010B2/ja not_active Expired - Fee Related
- 2007-04-17 AT AT07724319T patent/ATE499120T1/de active
- 2007-04-17 CN CN200780018981.0A patent/CN101454028B/zh not_active Expired - Fee Related
- 2007-04-17 DK DK07724319.4T patent/DK2029184T3/da active
- 2007-04-17 KR KR1020087031372A patent/KR101417148B1/ko active IP Right Grant
- 2007-04-17 WO PCT/EP2007/003382 patent/WO2007137653A1/en active Application Filing
- 2007-04-17 PL PL07724319T patent/PL2029184T3/pl unknown
- 2007-04-17 PT PT07724319T patent/PT2029184E/pt unknown
- 2007-04-17 MX MX2008014852A patent/MX2008014852A/es active IP Right Grant
- 2007-04-17 BR BRPI0712910A patent/BRPI0712910B8/pt not_active IP Right Cessation
- 2007-04-17 US US11/736,518 patent/US9421302B2/en active Active
- 2007-04-17 ES ES07724319T patent/ES2361574T3/es active Active
- 2007-04-17 AU AU2007268175A patent/AU2007268175B2/en not_active Ceased
- 2007-04-17 CA CA2651827A patent/CA2651827C/en active Active
- 2007-04-17 DE DE602007012693T patent/DE602007012693D1/de active Active
-
2012
- 2012-10-29 JP JP2012237629A patent/JP5695627B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-17 US US14/828,284 patent/US9724449B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009538285A (ja) | 2009-11-05 |
EP2029184B1 (en) | 2011-02-23 |
ATE499120T1 (de) | 2011-03-15 |
EP2029184A1 (en) | 2009-03-04 |
CA2651827C (en) | 2013-11-26 |
US9421302B2 (en) | 2016-08-23 |
KR101417148B1 (ko) | 2014-07-08 |
JP5298010B2 (ja) | 2013-09-25 |
US9724449B2 (en) | 2017-08-08 |
JP2013017842A (ja) | 2013-01-31 |
ES2361574T3 (es) | 2011-06-20 |
CN101454028B (zh) | 2014-06-04 |
DK2029184T3 (da) | 2011-05-02 |
US20070275028A1 (en) | 2007-11-29 |
PT2029184E (pt) | 2011-03-07 |
AU2007268175B2 (en) | 2013-05-23 |
BRPI0712910A2 (pt) | 2012-10-02 |
BRPI0712910B8 (pt) | 2021-05-25 |
KR20090017635A (ko) | 2009-02-18 |
US20150352253A1 (en) | 2015-12-10 |
PL2029184T3 (pl) | 2011-08-31 |
MX2008014852A (es) | 2008-12-05 |
WO2007137653A1 (en) | 2007-12-06 |
CA2651827A1 (en) | 2007-12-06 |
CN101454028A (zh) | 2009-06-10 |
BRPI0712910B1 (pt) | 2018-07-17 |
DE602007012693D1 (de) | 2011-04-07 |
AU2007268175A1 (en) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5695627B2 (ja) | 骨造成のための注射用フィブリン組成物 | |
JP5315233B2 (ja) | 注入可能な骨空隙充填剤 | |
US20100284919A1 (en) | Injectable Radio-Opaque Compositions for Tissue Augmentation | |
Yuan et al. | Technologies for Use in Indirect Distraction Procedures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140417 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140513 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141126 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5695627 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |